ATE286405T1 - Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen - Google Patents

Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen

Info

Publication number
ATE286405T1
ATE286405T1 AT94917379T AT94917379T ATE286405T1 AT E286405 T1 ATE286405 T1 AT E286405T1 AT 94917379 T AT94917379 T AT 94917379T AT 94917379 T AT94917379 T AT 94917379T AT E286405 T1 ATE286405 T1 AT E286405T1
Authority
AT
Austria
Prior art keywords
toxins
insensitivity
preventing
adverse effects
therapeutic uses
Prior art date
Application number
AT94917379T
Other languages
English (en)
Inventor
Stephen S Arnon
Original Assignee
Stephen S Arnon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stephen S Arnon filed Critical Stephen S Arnon
Application granted granted Critical
Publication of ATE286405T1 publication Critical patent/ATE286405T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT94917379T 1993-05-14 1994-05-12 Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen ATE286405T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6211093A 1993-05-14 1993-05-14
PCT/US1994/005345 WO1994026308A1 (en) 1993-05-14 1994-05-12 A method to prevent side effects and insensitivity to the therapeutic uses of toxins

Publications (1)

Publication Number Publication Date
ATE286405T1 true ATE286405T1 (de) 2005-01-15

Family

ID=22040286

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94917379T ATE286405T1 (de) 1993-05-14 1994-05-12 Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen

Country Status (6)

Country Link
EP (1) EP0699078B1 (de)
JP (1) JPH09500869A (de)
AT (1) ATE286405T1 (de)
DE (1) DE69434220T2 (de)
ES (1) ES2236692T3 (de)
WO (1) WO1994026308A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545126B1 (en) 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins
FR2793681B1 (fr) † 1999-05-18 2001-06-22 Oreal Utilisation d'au moins un inhibiteur d'au moins un canal calcique dans le traitement des rides
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9916810D0 (en) * 1999-07-16 1999-09-22 Cancer Res Campaign Tech Killing cells
US6846484B2 (en) * 2001-12-28 2005-01-25 Regents Of The University Of Minnesota DTAT fusion toxin
FR2846885B1 (fr) * 2002-11-13 2004-12-24 Oreal Utilisation d'une association de composants a effet synergique inhibiteur de canaux calciques pour prevenir ou traiter les ridules
US7071167B2 (en) 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines

Also Published As

Publication number Publication date
DE69434220T2 (de) 2005-12-22
JPH09500869A (ja) 1997-01-28
EP0699078A1 (de) 1996-03-06
ES2236692T3 (es) 2005-07-16
WO1994026308A1 (en) 1994-11-24
EP0699078B1 (de) 2005-01-05
DE69434220D1 (de) 2005-02-10

Similar Documents

Publication Publication Date Title
DE69333951D1 (de) Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität
ATE380875T1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
ATE32730T1 (de) Indikatormarkierte konjugate von metallothionein und zielsuchenden, biologisch aktiven molekuelen.
EP1421948A3 (de) Verwendung von Botulinum Toxine zur Behandlung vom Schwitzen bei Menschen
DE69329877D1 (de) Von L Protein abgeleitete Immunoglobulin-bindende Proteine und deren anwendungen
PL316449A1 (en) Combinations of thrombolytically active proteins and coagulants and their application
NO951740D0 (no) Preparater av eikebarkekstrakt, beslektede syntetiske preparater og fremgangsmåte for anvendelse av disse
DE69434384D1 (de) Metalkomplexbildner
ATE111519T1 (de) Familie von modifizierten antikörpern mit hoher affinität zur behandlung von krebs.
ATE304371T1 (de) Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
ATE286405T1 (de) Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
ZA947783B (en) Method of treating depressed reticuloendothelial system function
TR199800717T2 (xx) Amyotrofik lateral skleroz tedavisine y�nelik ila� haz�rlamak i�in
ES2106183T3 (es) Suero antiveneno.
GR3005362T3 (de)
DE3579573D1 (de) Logisches gatter mit "verdrahteter" und-funktion-eingangsstufe unter verwendung von feldeffekttransistoren.
DE69026371D1 (de) Heilmittel und verfahren zur inhibierung der vaskularisierung von tumoren
ATE55620T1 (de) Verfahren zur herstellung von interferon.
AU4312093A (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
EA199800819A1 (ru) Способ лечения биполярного расстройства
DE69330246D1 (de) Impfstoffe auf der basis von streptokinase
ATE147983T1 (de) Transdermales therapeutisches system mit pentylentetrazol als wirkstoff
DE69228121D1 (de) Schweineadipozytenantigene und ihre verwendung zur immunologischen kontrolle von fett

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties